Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

bout the future of this new anticancer drug candidate," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer.  

Side effects were generally manageable with dose-limiting toxicity consisting primarily of Grade 3 diarrhea (20-23%) typically occurring after three months of therapy for both schedules.   Neuropathy and alopecia were minimal with only one patient experiencing G2 alopecia in the study.  Both neuropathy and alopecia are significant adverse events commonly associated with standard breast cancer therapies [Safety Tables, Figures D and E].

NKTR-102 Phase 2 Data Presentation in Metastatic Breast Cancer

  • Awada et. al., Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).Abstract #1034, Poster Board #24Poster Discussion Session:  Breast Cancer - Triple-negative/Cytotoxics/Local Therapy  Session Date and Time:  Saturday, June 4, 2011, 2:00 PM – 6:00 PM, Central TimeLocation:  E450bFigure A: Efficacy Table: Objective Tumor Response Rate by RECIST (Investigator Assessment)Response by RECIST v 1.0NKTR-102145 mg/m2q14d NKTR-102145 mg/m2q21d TOTALN

    31*

    35

    66ORR (confirmed + unconfirmed)

    11 (35%)

    11 (31%)

    22 (33%)ORR (confirmed)

    10 (32%)

    9 (26%)

    19 (29%)CR (confirmed)

    2 (7%)

    0

    2 (3%)PR (confirmed)

    8 (26%)

    9 (26%)

    17 (26%)SD

    12 (39%)

    16 (46%)

    28 (42%)PD

    9 (29%)

    10 (29%)

    19 (29%)Median duration of response

    8.3 months

    4.4 months

    5.8 monthsClinical benefit

    (CR+PR+SD>6 months)

    13 (42%)

    17 (49%)

    30 (46%)Median progression-free survival**

    3.5 months

    5.3 months

    4.6 monthsMedian overall survival**

    8.8 months

    13.1 months

    10.3 months
    '/>"/>


  • SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
    2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
    3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
    5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
    6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
    9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
    10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
    11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, 2014 ... entered into an exclusive technology development partnership with ... agents to image CD4+ positive immune T cells. ... capability to precisely diagnose and determine therapeutic options ... The ability to image CD4+ T-cells will also ...
    (Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
    (Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
    Breaking Medicine Technology:ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
    (Date:9/17/2014)... A ball gown is the most formal ... full-skirted gown reaching the floor, made of luxurious fabric, ... occasion gown manufacturer and retailer, has delightedly unveiled its ... gowns are offered at discounted rates. , Most versions ... gowns are typically worn with a stole (a formal ...
    (Date:9/17/2014)... September 18, 2014 The National Resident ... Match , a comprehensive analysis of the relationship between ... preferred specialty. The new edition is based on ... specialty for U.S. allopathic medical school senior students and ... be able to provide this new edition of Charting ...
    (Date:9/17/2014)... September 17, 2014 In its latest ... drug and alcohol treatment program that gets clients off ... foundation in recovery they can believe in, is exploring ... 20% of Americans who are afflicted with depression are ... Forever Recovery’s CEO Per Wickstrom . “Unfortunately, these ...
    (Date:9/17/2014)... for the very healthy. Astronauts are selected for ... psychological standards to prepare them for any unknown ... average people can now fly for enjoyment. The ... about what medical conditions or diseases should be ... most medical conditions have never been studied for ...
    (Date:9/17/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... member of the therapeutic care team that is making a ... and around the world: dogs. , “Studies show ... and stress levels in recovering addicts,” commented Best Drug Rehabilitation’s ...
    Breaking Medicine News(10 mins):Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3Health News:Space: The final frontier… open to the public 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2
    ... surgeon Alexander Vaccaro, M.D., timing of surgery is crucial in ... of great argument among the orthopaedic surgeons. ,Should ... to try to limit the damage to the spinal cord ... make a difference in how a patient ultimately fares, as ...
    ... disease, has been established by researchers from the Jean Mayer// ... , ,The study involved examination of apolipoprotein A5 ... a vital role in fat metabolism in the blood. A ... heart disease, which can be altered by consumption of high ...
    ... juices is not linked with preschoolers being overweight, ... in the October issue of Pediatrics, the// leading ... Pediatrics (AAP). This latest analysis of the largest ... Health and Nutritional Examination Survey 1999-2002) finds no ...
    ... Minister Ram Vilas Paswan promises a new policy for the ... subsidised treatment for// tuberculosis, AIDS and cancer. ,"By ... district headquarters that will offer free medication to the poor," ... will be stocked with the help of the drug manufacturers ...
    ... against flu, researchers at the University of Wisconsin-Madison have ... broad protection// against influenza viruses, including deadly avian influenza. ... (Oct. 4, 2006) in the Journal of Virology, describes ... molecule -- that effectively blocks the influenza virus from ...
    ... Lucknow: An Uttar Pradesh villager suffering from a serious ... floor of a premier hospital here//, apparently because he ... man jumped out of a window of the nephrology ... Medical Sciences, where he was being treated, hospital sources ...
    Cached Medicine News:Health News:Study on Timing of Spinal Surgery 2Health News:Study on Timing of Spinal Surgery 3Health News:The interplay of genes, diet and heart disease 2Health News:The interplay of genes, diet and heart disease 3Health News:The interplay of genes, diet and heart disease 4Health News:Fruit Juice Intake Among Preschool Children Not Associated with Weight 2Health News:Free Medicines, Health Insurance for Poor Soon: Paswan 2Health News:New Drug Blocks Influenza, Including Bird Flu Virus 2Health News:New Drug Blocks Influenza, Including Bird Flu Virus 3
    ... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
    ... Minifold I system consists of four basic components: ... and metal clamping plate (see diagram). The sample ... producing spots, dots, or slots (see below). All ... as an accessory plate in conjunction with a ...
    ... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
    ... and Bio-Dot SF (slot format) microfiltration units ... or nucleic acid in solution onto nitrocellulose ... be accommodated by using interchangeable templates to ... slot format Bio-Dot SF apparatus. Each is ...
    Medicine Products: